Secondary Listing on Frankfurt Exchange

MedPal AI plc("MedPal AI" or the "Company")

Secondary Listing on the Frankfurt Stock Exchange

MedPal AI (AIM: MPAL, FRA: Z1N), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to announce that the Company's ordinary shares have been admitted to trading on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse, "FRA"), operated by Deutsche Börse AG, with trading under the ticker Z1N commencing today.

Listing Details

The Frankfurt listing is a secondary listing and sits alongside the Company's primary quotation on the AIM market of the London Stock Exchange. Trading in the Company's shares on the AIM market will continue as previously and the Company will continue to make all regulatory disclosures via RNS.

Strategic Rationale

Germany represents one of Europe's largest and most dynamic private investor markets. According to figures published by Deutsches Aktieninstitut, the number of retail investors in Germany reached a new record high of 14.1 million in 2025, driven in particular by younger investors up to the age of 39 who now represent the largest investor cohort.

This growing pool of engaged private investors, combined with the Frankfurt Stock Exchange's position as the third largest exchange in Europe by market capitalisation and its role as a trading venue primarily serving private investors with access to over one million securities, provides the Company with a significant opportunity to broaden its shareholder base and increase trading liquidity.

The rise of low-cost European neo-broker platforms has further democratised access to dual-listed securities on the German exchanges, enabling retail investors to trade at minimal cost. The Board believes that a dual listing in Frankfurt positions MedPal AI to capitalise on these favourable structural trends and to build visibility among a new and substantial audience of European retail investors.

The Frankfurt listing also coincides with the Company's planned expansion into the German market. MedPal AI has launched a German-language version of its AI-powered wellness application to coincide with the listing, marking the first step in the Company's European growth strategy. Over the next six months, the Company intends to extend additional MedPal services into Germany, leveraging the country's rapidly growing digital health market which is expected to expand at a compound annual growth rate in excess of 20% through to 2030.

In support of the Frankfurt listing, MedPal AI will be presenting at an investor event in Germany in mid-March 2026, providing an opportunity to engage directly with the German investment community and to introduce the Company's integrated AI healthcare platform to a broader European audience.

Company page on the Deutsche Börse: https://live.deutsche-boerse.com/equity/medpal-ai-plc-ls-0002?mic=XFRA

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"We are delighted to announce our secondary listing on the Frankfurt Stock Exchange, which represents an important milestone in MedPal AI's growth as a European digital health company. Germany is home to one of the continent's most active and expanding retail investor communities, and a dual listing provides us with access to this significant pool of capital and visibility.

"The timing of this listing is deliberate. By simultaneously launching a German-language version of our AI wellness app and committing to a broader rollout of MedPal services across Germany over the coming months, we are not simply listing our shares in a new market - we are entering the market as a business. Our presentation to German investors in March will provide an opportunity to demonstrate the strength of our integrated healthcare platform and our ambitions for the European market."

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.